Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 7/20 | 0.54 |
| ▸ | EP300 | Q09472 | 2/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.47 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.47 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.45 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | G6PD | P11413 | 1/20 | 0.44 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29662262 | 1.00 | IDO1 (0.54) | IDO1EP300HSP90AA1KAT2BKAT8 | |
| SCHEMBL6241238 | 0.91 | TRPV1 (0.50) | IDO1HSP90AA1CDC25BMEN1KMT2A | |
| SCHEMBL27801232 | 0.85 | MEN1 (0.55) | IDO1EP300KAT2BKAT8PSD | |
| SCHEMBL19002107 | 0.84 | MEN1 (0.43) | MEN1KMT2AGAANPC1RAB9A | |
| SCHEMBL9125816 | 0.83 | IDO1 (0.59) | IDO1EP300HSP90AA1KAT2BKAT8 | |
| SCHEMBL593484 | 0.83 | RXFP1 (0.62) | MEN1KMT2AGAANPC1RAB9A | |
| SCHEMBL12596121 | 0.83 | RXFP1 (0.43) | HSP90AA1MEN1KMT2AGAANPC1 | |
| SCHEMBL4689617 | 0.83 | AAK1 (0.44) | CDC25BMEN1KMT2AGAANPC1 | |
| SCHEMBL628821 | 0.82 | MEN1 (0.45) | CDC25BMEN1KMT2AGAANPC1 | |
| SCHEMBL2952822 | 0.82 | MEN1 (0.42) | MEN1KMT2AGAANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634406-B2 | Inhibitor of p38 MAP kinase | RESPIVERT LTD. (GB) | 2023-04-25 | — | — | US | disclosed |
| US-20220098162-A1 | APHTHYLAMINE COMPOUND AND BIOLOGICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | HENAN RADIOMEDICAL SCIENCE AND TECH CO LTD (CN) | 2022-03-31 | — | — | US | disclosed |
| US-20220098162-A1 | APHTHYLAMINE COMPOUND AND BIOLOGICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | HENAN RADIOMEDICAL SCIENCE AND TECH CO LTD (CN) | 2022-03-31 | — | — | US | disclosed |
| CN-114144410-A | Polyarylurea derivatives and their use in the treatment of muscular diseases | 阿纳格纳斯生物技术股份有限公司 | 2022-03-04 | — | — | CN | disclosed |
| US-11142515-B2 | Pyrazolyl-ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2021-10-12 | — | — | US | disclosed |
| US-20210179584-A1 | INHIBITOR OF p38 MAP KINASE | RESPIVERT LIMITED (GB) | 2021-06-17 | — | — | US | disclosed |
| WO-2021037090-A1 | NAPHTHYLAMINE COMPOUND AND BIOLOGICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 河南省锐达医药科技有限公司 | 2021-03-04 | — | — | WO | disclosed |
| WO-2021037090-A1 | NAPHTHYLAMINE COMPOUND AND BIOLOGICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 河南省锐达医药科技有限公司 | 2021-03-04 | — | — | WO | disclosed |
| EP-3418279-B1 | DRY POWDER PHARMACEUTICAL FORMULATION | RESPIVERT LTD (GB) | 2021-01-20 | — | — | EP | disclosed |
| US-10815217-B2 | Inhibitor of p38 MAP kinase | RESPIVERT LTD. (GB) | 2020-10-27 | — | — | US | disclosed |
| US-20030083333-A1 | 1,4-Disubstituted benzo-fused compounds | BOEHRINGER INTELHEIM PHARMACEUTICALS, INC. | 2003-05-01 | — | — | US | disclosed |
| US-6525046-B1 | Inhibits inflammatory cytokines such as interleukin-1 and tumor necrosis factor; 1-(5-(2-hydroxy-1,1-dimethyl-ethyl) -2-p-tolyl-2H-pyrazol-3-yl)-3- (4-(2- morpholin-4-yl-ethoxy)-naphthalen-1-yl)-urea | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-02-25 | — | — | US | disclosed |
| WO-2003005999-A2 | METHODS OF TREATING CYTOKINE MEDIATED DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-01-23 | — | — | WO | disclosed |
| US-20030008868-A1 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-01-09 | — | — | US | disclosed |
| WO-2002092576-A1 | DIARYLUREA DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-11-21 | — | — | WO | disclosed |
| US-6476023-B1 | Aromatic heterocyclic compounds as anti-inflammatory agents | BOEHRINGEN INGELHEIM PHARMACEUTICALS, INC. | 2002-11-05 | — | — | US | disclosed |
| WO-2002083628-A1 | 1,4-DISUBSTITUTED BENZO-FUSED COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| EP-1163236-A1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2001-12-19 | — | — | EP | disclosed |
| US-6297381-B1 | INHIBIT THE RELEASE OF INFLAMMATORY CYTOKINES SUCH AS INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR, UREAS OR THIOUREAS SUBSTITUTED BY A PYRROLE OR THIOPHENE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-10-02 | — | — | US | disclosed |
| WO-2000055152-A1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008868-A1 | Compounds useful as anti-inflammatory agents | TNF, MPO, PTGES | IDO1 1202/4885EP300 181/4885HSP90AA1 689/4885 |
| US-20030083333-A1 | 1,4-Disubstituted benzo-fused compounds | RELA, NFKBIA, NQO1 | IDO1 1535/4885EP300 137/4885HSP90AA1 806/4885 |
| US-20220098162-A1 | APHTHYLAMINE COMPOUND AND BIOLOGICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | HASPIN, SLC7A1, INMT | IDO1 1959/4885EP300 3198/4885HSP90AA1 2834/4885 |
| US-10815217-B2 | Inhibitor of p38 MAP kinase | MAPK1, MAPKAPK2, MAP3K1 | IDO1 842/4885EP300 1570/4885HSP90AA1 2723/4885 |
| US-20210179584-A1 | INHIBITOR OF p38 MAP KINASE | MAPK1, MAPKAPK2, MAPK10 | IDO1 3371/4885EP300 444/4885HSP90AA1 133/4885 |
| US-11142515-B2 | Pyrazolyl-ureas as kinase inhibitors | MAPK1, MAP3K1, MAP3K8 | IDO1 2064/4885EP300 572/4885HSP90AA1 830/4885 |
| US-11634406-B2 | Inhibitor of p38 MAP kinase | MAPK1, MAPKAPK2, MAPK10 | IDO1 3371/4885EP300 444/4885HSP90AA1 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.